Ken Griffin Dexcom Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dexcom Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 571,100 shares of DXCM stock, worth $67.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

571,100

Previous 953,500 40.1%

Holding current value

$67.8 Million

Previous $118 Million 33.05%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$114.22 - $140.1 $192 Million - $236 Million	-1,683,378 Reduced 70.86%	692,382 $96 Million
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $108 Million - $178 Million	1,432,110 Added 151.76%	2,375,760 $295 Million
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $59 Million - $94.6 Million	685,606 Added 265.69%	943,650 $88 Million
Q2 2023 Aug 14, 2023	SELL	$112.47 - $130.98 $425 Million - $495 Million	-3,780,330 Reduced 93.61%	258,044 $33.2 Million
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $188 Million - $222 Million	1,805,530 Added 80.86%	4,038,374 $469 Million

Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $135 Million - $194 Million	1,583,317 Added 243.76%	2,232,844 $253 Million
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $185 Million - $228 Million	-2,421,347 Reduced 78.85%	649,527 $52.3 Million
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $188 Million - $366 Million	2,757,773 Added 880.79%	3,070,874 $229 Million
Q1 2022 May 16, 2022	BUY	$94.08 - $130.2 $15.4 Million - $21.4 Million	164,176 Added 110.24%	313,101 $160 Million
Q4 2021 Feb 14, 2022	SELL	$129.87 - $162.82 $4.54 Million - $5.69 Million	-34,923 Reduced 19.0%	148,925 $20 Million
Q3 2021 Nov 15, 2021	BUY	$106.71 - $143.18 $19.2 Million - $25.7 Million	179,527 Added 4154.76%	183,848 $101 Million
Q2 2021 Aug 16, 2021	SELL	$80.99 - $107.93 $9.93 Million - $13.2 Million	-122,557 Reduced 96.59%	4,321 $461,000
Q1 2021 May 17, 2021	BUY	$84.79 - $104.74 $10.2 Million - $12.6 Million	120,749 Added 1970.13%	126,878 $45.6 Million
Q4 2020 Feb 16, 2021	SELL	$78.0 - $104.5 $10.4 Million - $14 Million	-133,890 Reduced 95.62%	6,129 $2.27 Million
Q3 2020 Nov 16, 2020	SELL	$95.51 - $112.95 $3.74 Million - $4.42 Million	-39,140 Reduced 21.85%	140,019 $57.7 Million
Q2 2020 Aug 14, 2020	SELL	$62.68 - $105.34 $9.87 Million - $16.6 Million	-157,393 Reduced 46.77%	179,159 $72.6 Million
Q1 2020 May 15, 2020	SELL	$47.79 - $75.63 $4.66 Million - $7.38 Million	-97,538 Reduced 22.47%	336,552 $90.6 Million
Q4 2019 Feb 14, 2020	BUY	$36.62 - $57.29 $11.7 Million - $18.3 Million	319,006 Added 277.19%	434,090 $95 Million
Q3 2019 Nov 14, 2019	SELL	$35.53 - $43.8 $12.7 Million - $15.6 Million	-356,217 Reduced 75.58%	115,084 $4.29 Million
Q2 2019 Aug 14, 2019	BUY	$27.84 - $38.92 $5.61 Million - $7.85 Million	201,638 Added 74.77%	471,301 $70.6 Million
Q1 2019 May 15, 2019	SELL	$28.07 - $38.18 $561,596 - $763,867	-20,007 Reduced 6.91%	269,663 $0
Q4 2018 Feb 14, 2019	SELL	$26.99 - $37.37 $18.6 Million - $25.7 Million	-688,671 Reduced 70.39%	289,670 $8.68 Million
Q3 2018 Nov 13, 2018	BUY	$23.35 - $36.72 $7.54 Million - $11.9 Million	323,017 Added 49.29%	978,341 $0
Q2 2018 Aug 10, 2018	BUY	$17.54 - $25.22 $8.37 Million - $12 Million	477,447 Added 268.41%	655,324 $0
Q1 2018 May 11, 2018	BUY	$13.06 - $18.54 $1.54 Million - $2.19 Million	117,890 Added 196.53%	177,877 $13.2 Million
Q4 2017 Feb 09, 2018	SELL	$11.12 - $15.38 $1.48 Million - $2.04 Million	-132,661 Reduced 68.86%	59,987 $3.44 Million
Q3 2017 Nov 09, 2017	BUY	$11.36 - $18.98 $2.19 Million - $3.66 Million	192,648	192,648 $9.43 Million

Others Institutions Holding DXCM

# of Institutions

1,123

Shares Held

352M

Call Options Held

4.19M

Put Options Held

4.54M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $45.9B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account